GTBP
GT Biopharma, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 30 ▼ GT Biopharma filed an S-1 registration statement to register up to 9…
- May 22 ▼ GT Biopharma received a Nasdaq notice granting an additional 180-day…
- Sep 4 Trading halt: Trading Halt: GTBP, T1 (News Pending)
- Sep 4 Trading halt: Trading Halt: GTBP, T3 (News and Resumption Times)
- Sep 8 Trading halt: Halt Resumed: GTBP, trading resumed after T3 (News and Res…
- Sep 15 ▲ Short interest falls 93.3% to 256.6K
- Sep 15 ▼ GT Biopharma entered into a securities purchase agreement to sell up…
- Sep 15 Trading halt: Halt Resumed: GTBP, trading resumed after LUDP (Volatility…
- Sep 15 Trading halt: Trading Halt: GTBP, LUDP (Volatility Trading Pause)
- Oct 9 ▼ GT Biopharma filed an S-1 registration statement to register up to 1…
- Oct 13 ▼ GT Biopharma is holding a special meeting on November 11, 2026 to vo…
- Oct 21 ▼ GT Biopharma's S-1 registration (File No. 333-299408) became effecti…
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q2 2026: 3 added (0 new), 2 trimmed or exited.
- Short sellersSTEADY
Short interest −11.6% to 246.5K shares. 3.2 days to cover, ≈12.0% of shares.
- TrendDOWNTREND
42% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| OSAIC HOLDINGS, INC. | ADD | $18.9K |
| MORGAN STANLEY | ADD | $11.1K |
| ROYAL BANK OF CANADA | DOUBLED | $4.0K |
| BNP PARIBAS FINANCIAL MARKETS | TRIM | $3.00 |
| UBS Group AG | NEAR_EXIT | $1.00 |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | $120.2K |
| UBS Group AG | DOUBLED | $18.8K |
| LPL Financial LLC | DOUBLED | $12.4K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Dec 2024Price is below the lowest target. Median implies +2022%.Targets as of Nov 12, 2026.
| Date | Firm | Rating |
|---|---|---|
| Dec 2, 2024 | Roth MKM INITIATE | Buy |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | None | None | No data | $0.00 |
| Next Q | None | None | No data | $0.00 |
| Current FY | None | None | No data | $0.00 |
| Next FY | None | None | No data | $0.00 |
Short side
FINRA· Oct 30, 2026| Sep 15, 2026 | Volatility Pause | Resumed |
| Sep 4, 2026 | Resumption Scheduled | Resumed |
SecBot reports
11 filings · 1 press release · 0 bullish · 7 bearish · 4 neutral- NEUTRAL PRESS-RELEASENov 16, 2026
GT Biopharma reported Q3 2026 net loss of $3.5M vs net income of $8.3M in Q3 2025, driven by a non-cash change in fair value of Greenshoe Rights liability that did not recur. Cash balance of ~$10M provides runway into Q3 2027.
🔒 Fresh report (last 24h), subscribers only
- BEARISH EFFECTOct 21, 2026
GT Biopharma's S-1 registration (File No. 333-299408) became effective on October 20, 2026…
The effectiveness opens the door for selling stockholders to immediately resell shares, adding near-term selling pressure. Monitor for any Form 4 filings or prospectus supplements indicating actual…
- BEARISH DEF 14AOct 13, 2026
GT Biopharma is holding a special meeting on November 11, 2026 to vote on four proposals: (1)…
Monitor the special meeting vote outcome on November 11, 2026. If Proposal 3 passes, expect significant dilution overhang as the $6.10 conversion/exercise price is well above current trading levels…
- BEARISH S-1Oct 9, 2026
GT Biopharma filed an S-1 registration statement to register up to 13,502,835 shares of common…
Monitor for selling pressure as institutional holders (Bristol, Five Narrow Lane, Rainforest Partners) begin distributing their registered shares. The greenshoe rights represent a potential future…
All GTBP filing & press-release reports (12)
- PRESS-RELEASE reportNov 16, 2026
- EFFECT reportOct 21, 2026
- DEF 14A reportOct 13, 2026
- S-1 reportOct 9, 2026
- 8-K reportSep 25, 2026
- 8-K reportSep 15, 2026
- 8-K reportSep 3, 2026
- PRESS-RELEASE reportAug 14, 2026
- 8-K reportMay 22, 2026
- S-1 reportApr 30, 2026
- 8-K reportApr 7, 2026
- PRESS-RELEASE reportMar 2, 2026